0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Solutions for RSV vaccine and drug development

Solutions for RSV vaccine and drug development

Solutions for RSV vaccine and drug development
Background
Human Respiratory Syncytial Virus, (HRSV) is a negative-stranded RNA virus of the Pneumoviridae family (genus Orthopneumovirus) that can inflict potentially deadly respiratory tract infections in infants, the elderly, and immunocompromised individuals leading to approximately 50,000 deaths of children under 5 per year.
The HRSV genome is about 15.2kb in length and encodes for 11 proteins. RSV surface fusion protein (F) and attachment (G) glycoproteins play important roles in mediating infection and are both major targets of the humoral immune response. RSV F is well conserved while G is highly variable, with the two antigenic subgroups of RSV (A and B) being defined primarily by differences in the G protein. Vaccine and therapeutics development efforts have largely focused on RSV F.
Nature reviews. Drug discovery vol. 20,7 (2021): 531-550.
Solutions for RSV vaccine and drug development

(10.1038/s41579-019-0149-x)

RSV F is a type I fusion protein that rearranges from a metastable prefusion conformation to a highly stable postfusion structure.
The epitopes of RSV-F protein and antibody binding
The epitopes of RSV-F protein and antibody binding
Based on the structural research on RSV F protein, there are at least 7 different antigenic epitopes that have been identified, termed Site Ø, I, II, III, IV, V, and a quaternary dependent (QD) site. Of these sites, only I, II, and IV are exposed on the post-F form. The post-F form has been found to elicit relatively weaker neutralizing antibodies that fail to stop infection. The pre-fusion form has been proven to induce more efficient neutralizing antibodies, while the post-fusion form can be used as a control for screening for pre-specific antibody.
RSV vaccines and drugs R&D solutions
Product type Molecule Cat. No. Product Description
Main Features

Provide native, structurally verified trimeric Pre-F/Post-F/G proteins, Pre-F/Post-F broadly & specific antibodies and ELISA kits;

Over 90% purity verified by SDS-PAGE and SEC-MALS

Binding activity of Pre-F and Post-F proteins verified through ELISA with their respective specific antibodies.

High immunogenicity: native trimeric antigens can induce higher neutralizing antibody titers.

Assay Data
Antigens
Antigens

The purity of HRSV (A) Fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) is more than 90% and the molecular weight of this protein is around 175-200 kDa verified by SEC-MALS.

Antigens

Immobilized HRSV (A) Fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 2 μg/mL (100 μL/well) can bind Anti-Fusion glycoprotein F0 Antibody, Human IgG1 (D25) with a linear range of 0.2-1 ng/mL (QC tested).

Antibodies
Antibodies

Immobilized HRSV (A) Pre-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-RSV-Pre-F0 specific Antibody, Human IgG1 (12C6) (Cat. No. RS0-S286) with a linear range of 0.2-2 ng/mL. HRSV (A) Post-fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H6) is verified not recoginized by Monoclonal Anti-RSV-Pre-F0 specific Antibody, Human IgG1 (12C6) (Cat. No. RS0-S286) in low concentration (QC tested).


ELISA kits
ELISA kits

Detection of Pre-Fusion glycoprotein F0 (RSV) by sandwich-ELISA Assay.Immobilized Anti-Pre-Fusion glycoprotein F0 (RSV) Antibody can bind Pre-Fusion glycoprotein F0 (RSV). Detection was performed using HRP-Anti-Pre-Fusion glycoprotein F0 (RSV) Antibody with sensitivity of 3.1 ng/mL (QC tested).

>  Click to see more Core reagents for infectious disease research

ACRO Quality

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken